Express Scripts (ESRX) Stock Price & Analysis

ESRX$92.330.00 0.00%
Medical - PharmaceuticalsGrowth Stock
Compare
Market cap—Enterprise value$13.70BRevenue (TTM)$101.35BMarket position—

Score

56
Neutral
Value
59
Quality
41
Growth
67

AI Analysis

Snapshot

Express Scripts Holding is a mixed profile at 56/100 — Value 59, Growth 67, Quality 41. Under the hood: P/E 11.9, about 60% below its own multi-year median.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

59
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

67
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

41
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Express Scripts Holding Company (ESRX) last printed $92.33. Equity value is $0. Trailing earnings multiple 11.85. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2008200920102011201220132014201520162017
$21.98B$24.75B$44.97B$46.13B$93.86B$104.1B$100.89B$101.75B$100.29B$100.06B

About

Express Scripts, established in 1986, functions as a pharmacy benefit management (PBM) enterprise. It offers a comprehensive array of integrated services, including the processing of prescription claims, home delivery of medications, strategic management of drug formularies, specialized pharmaceutical support via its Accredo division, and insightful analytics derived from drug usage data. The company became a subsidiary of Cigna in December 2018, following its acquisition for $54 billion.

Express Scripts (ESRX) Stock Price & Analysis

ESRX price $92.33 0.00 0.00%

Ticker
ESRX
Price
$92.33
Change
0.00 0.00%
Market cap
$0
P/E
11.85
Dividend yield
0.00%
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Stocklytics score
56
Value
59
Quality
41
Growth
67

Stocklytics score rationale: value 59, quality 41, growth 67.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener